934628-27-0
Chemical Structure
Nilofabicin
Synonym(s): CG-400549
- CAS No.: 934628-27-0
- Formula:C19H20N2O2S
- Molecular Weight:340.44
IUPAC Name: 1-(3-amino-2-methylbenzyl)-4-(2-(thiophen-2-yl)ethoxy)pyridin-2(1H)-one
InChIKey: YCLREGRRHGLOAK-UHFFFAOYSA-N
SMILES: O=C1C=C(OCCC2=CC=CS2)C=CN1CC3=CC=CC(N)=C3C
Biological Activity: Nilofabicin (CG-400549) is an anti-bacterialagent that targets FabI. Nilofabicin shows high selectivity for the genus Staphylococcus and weak activity against most Gram-negative bacteria. Nilofabicin inhibits bacterial fatty acid biosynthesis, blocks phospholipid synthesis, and disrupts the structure of bacterial cell membranes. Nilofabicin exhibits in vivo antibacterial efficacy in a mouse model of systemic Staphylococcus aureus infection. Nilofabicin can be used in studies related to bacterial infections[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Nilofabicin | 99.58% | Nilofabicin (CG-400549) is an anti-bacterialagent that targets FabI. Nilofabicin shows high selectivity for the genus Staphylococcus and weak activity against most Gram-negative bacteria. Nilofabicin inhibits bacterial fatty acid biosynthesis, blocks phospholipid synthesis, and disrupts the structure of bacterial cell membranes. Nilofabicin exhibits in vivo antibacterial efficacy in a mouse model of systemic Staphylococcus aureus infection. Nilofabicin can be used in studies related to bacterial infections. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Nilofabicin (Standard) | ≥98% | Nilofabicin (Standard) is an analytical standard for Nilofabicin (HY-111071). This product is intended for research and analytical applications. Nilofabicin (CG-400549) is an anti-bacterialagent that targets FabI. Nilofabicin shows high selectivity for the genus Staphylococcus and weak activity against most Gram-negative bacteria. Nilofabicin inhibits bacterial fatty acid biosynthesis, blocks phospholipid synthesis, and disrupts the structure of bacterial cell membranes. Nilofabicin exhibits in vivo antibacterial efficacy in a mouse model of systemic Staphylococcus aureus infection. Nilofabicin can be used in studies related to bacterial infections. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Kim BY, et al. Solid state of CG-400549, a novel FabI inhibitor: characterization, dissolution, transformation. Archives of pharmacal research. 2011 May;34(5):775-9. [Content Brief]
- [2]. Douglas EJA, et al. Novel antimicrobial strategies to treat multi-drug resistant Staphylococcus aureus infections. Microbial biotechnology. 2023 Jul;16(7):1456-1474. [Content Brief]
- [3]. Wang J, et al. Inhibitors of fatty acid synthesis in prokaryotes and eukaryotes as anti-infective, anticancer and anti-obesity drugs. Future medicinal chemistry. 2012 Jun;4(9):1113-51. [Content Brief]
